Recreation- and sport-led regeneration of urban water infrastructure. [PDF]
Book K.
europepmc +1 more source
SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher+12 more
wiley +1 more source
A Practice of “Activities of Making Maps” to Cultivate Space Cognition
Nobuki Watanabe
openalex +2 more sources
Integrated modeling activities for the James Webb Space Telescope: structural-thermal-optical analysis [PDF]
John D. Johnston+7 more
openalex +1 more source
Machine learning-assisted source identification and probabilistic ecological-health risk assessment of heavy metal(loid)s in urban park soils. [PDF]
Li J+6 more
europepmc +1 more source
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone+19 more
wiley +1 more source
History of the development of radiation protection standards for space activities
Warren K. Sinclair
openalex +1 more source
A Study of Children's Activity Spaces on Weekday and Saturday by Considering their Activity Partners
Norie Miwa+2 more
openalex +4 more sources
Research on the influence of spontaneous commercial space on the commercial vitality of historical and cultural districts. [PDF]
Wang R, Shang W, Zhang G.
europepmc +1 more source
Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan+8 more
wiley +1 more source